Literature DB >> 10370175

A dose-response study of epidural liposomal bupivacaine in rabbits.

J M Malinovsky1, P Le Corre, J F Meunier, F Chevanne, M Pinaud, R Leverge, F Legros.   

Abstract

Liposomes are drug delivery systems used to prolong local effects of bupivacaine. We studied the relationships between motor and hemodynamic changes and epidural doses of plain bupivacaine (P) and liposomal bupivacaine (L) in rabbits equipped with chronical lumbar epidural and femoral arterial catheters. Liposomal (phosphatidylcholine-cholesterol) suspensions contained 20 mg ml-1 of lipid, and different doses of bupivacaine (Lipo 7.5=7.5-; Lipo 3.7=3. 75-; Lipo 2.5=2.5-; Lipo 1.2=1.25-; and Lipo 0.7=0.65-mg of bupivacaine per ml). Forty rabbits were randomly assigned to five groups to receive epidural anesthesia (1 ml) as follows: Groups I to V received 0.65 to 7.5 mg of bupivacaine as P then as L. Release rate of bupivacaine from liposome was significantly slower using Lipo 3.7 than after Lipo 2.5 (Td was 3.9 h and 1.7 h respectively). Increasing the doses of L and P resulted in faster onset time for complete motor blockade and in a prolonged duration of motor effects. Liposomal formulation appears to be a powerful delivery system to prolong the motor effects of bupivacaine since E50 was lower and Emax higher than after the use of plain solution (E50 4.49+/-1.81 mg and Emax 152+/-40 min for P; and E50 2.61+/-0.23 mg and Emax 202+/-9 min for L). Hemodynamic changes were linearly related to doses of bupivacaine injected. The best bupivacaine-to-lipid ratio to prolong motor effects using our model was 3.75 mg and 20.0 mg respectively (Lipo 3.7).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10370175     DOI: 10.1016/s0168-3659(99)00062-0

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  5 in total

Review 1.  Safety and efficacy concerns of modern strategies of local anesthetics delivery.

Authors:  Mingxin Ji; Guoliang Liu; Yunfeng Cui; Peng Zhao
Journal:  3 Biotech       Date:  2020-07-06       Impact factor: 2.406

2.  Anti-nociceptive effects of bupivacaine-encapsulated PLGA nanoparticles applied to the compressed dorsal root ganglion in mice.

Authors:  Tao Wang; Olivia Hurwitz; Steven G Shimada; Daofeng Tian; Feng Dai; Jiangbing Zhou; Chao Ma; Robert H LaMotte
Journal:  Neurosci Lett       Date:  2018-02-03       Impact factor: 3.046

3.  Long-acting poly(DL:lactic acid-castor oil) 3:7-bupivacaine formulation: effect of hydrophobic additives.

Authors:  Marina Sokolsky-Papkov; Ludmila Golovanevski; Abraham J Domb; Carolyn F Weiniger
Journal:  Pharm Res       Date:  2011-06-30       Impact factor: 4.200

4.  Release Pattern of Liposomal Bupivacaine in Artificial Cerebrospinal Fluid.

Authors:  Ayşe Ünal Düzlü; Berrin Günaydın; Murat Kadir Şüküroğlu; İsmail Tuncer Değim
Journal:  Turk J Anaesthesiol Reanim       Date:  2016-02-01

5.  Prolonged duration local anesthesia with minimal toxicity.

Authors:  Hila Epstein-Barash; Iris Shichor; Albert H Kwon; Sherwood Hall; Michael W Lawlor; Robert Langer; Daniel S Kohane
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-13       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.